Latest
Sources
Trade Ideas
Speakers
Sign in
Go
Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25
Original source ↗
| February 14, 2026 at 19:04 UTC |
Finnhub - PFE
No analysis available.
Trade Ideas
Ticker
Direction
Speaker
Thesis
Time
PFE
LONG
Finnhub News
Oric Pharmaceuticals presented positive future development plans, including a significant Phase 3 trial target.
—